Jamie Dlux examines the checkered career of Stanislaw Burzynski , the founder of the Houston, Texas-based Burzynski Clinic. Burzyinski has pioneered the use of antineoplastons in the treatment of cancer. It’s an unconventional approach, which has led to a series of challenges to the clinic from the U.S. Food and Drug Administration.
While the FDA has been rebuffed by more than one grand jury, they have persisted in filing actions against Burzyinski, leading to considerable acrimony and debate. Is the agency really concerned about the caliber of Burzynski’s treatment or simply pushing a vendetta?